Sepsis Diagnostic Market Predicts Rise In Demand By 2026

Sepsis Diagnostic Market Predicts Rise In Demand
By 2026
Sepsis Diagnostic Market, By Product (Assay and Reagents, Blood Culture
Media, and Instruments), By Pathogen (Fungal Sepsis and Bacterial Sepsis), By
Method (Immunoassays, Flow Cytometry, Molecular Diagnosis, and Biomarker
Diagnosis), By Diagnostic Method (Conventional and Automated), By End User
(Hospital Laboratories, Diagnostic Laboratories, Academic and Research
Laboratories) - Global Industry Insights, Trends, Outlook, and Opportunity
Analysis, 2018-2026
Sepsis is life threatening complication caused due to the infection, which can result into organ failure,
tissue damage, and ultimately lead to death if left untreated. If sepsis progresses to septic shock, it
cause sudden drop in blood pressure and may leads to death of patient. Sepsis occurs due the infection
in any part of the body. However the most common site of infections leading to the sepsis are lungs,
abdomen, pelvis, and urinary tract. Click To Read More On Sepsis Diagnostic Market.
Patients suffering from impaired immune system due to illness or drugs, cancer treatment with
chemotherapy, splenectomy, sickle cell disease, and people who consume steroids and
immunosuppressant drugs are prone to sepsis. The symptoms associated with sepsis includes high fever
with temperature above 1010 F or temperature below 96.8 F, increased heart rate to 90 beats per
minute, high breathing rate to around 20 breaths per minute, tissue swelling and confirmed infection.
According to the Healthcare Cost and Utilization Project (HCUP) report submitted by Agency for
Healthcare Research and Quality (AHRQ) in 2016, septicemia accounted for the leading cause of
hospitalization in the U.S., owing to consuming more than US$ 24 billion each year.
Increasing prevalence of sepsis is resulting into high demand for sepsis diagnostic devices in the
market. According to the Sepsis Alliance report 2016, sepsis affects over 26 million people worldwide
and more than 5 million children each year. According to the Centers for Disease Control and
Prevention (CDC), more than 1.5 million people in the U.S. suffer from sepsis annually and around
2,50,000 Americans die each year due to sepsis.
Sepsis Diagnostic Market Taxonomy:
On the basis of product, sepsis diagnostic market segmented into:
•Assay and reagents
•Blood culture media
•Instruments
•Others
On the basis of pathogen, sepsis diagnostic market segmented into:
•Fungal sepsis
•Bacterial sepsis
•Gram-positive bacterial sepsis
•Gram-negative bacterial sepsis
•Other infectious pathogens
On the basis of methods, sepsis diagnostic market segmented into:
•Immunoassays
•Flow cytometry
•Molecular diagnosis
•Biomarker diagnosis
The treatment for sepsis varies depending upon the site and cause of infections. Early symptoms of
sepsis can be treated by visiting hospitals for diagnosis and treatment. However, severe sepsis and
sepsis shock are medical emergencies, which need quick medical attention. The treatment includes
rapid administration of antibiotic and intravenous fluid (IV fluid) to the patient detected with symptoms
of sepsis, as the risk of death form sepsis increases by 7.6% with every hour from the time of treatment
begins. Antibiotic treatment mainly includes broad spectrum antibiotic given by intravenous. The
antibiotics used in the sepsis treatment includes vancomycin, piperacillin, tazobactam, cefepime,
tobramycin, and aztreonam.
Ask For Sample Copy Of This Business Research Report :
https://www.coherentmarketinsights.com/insight/request-sample/1166
Key players in the sepsis diagnostic market:
Some of the key players operating in the sepsis diagnostic market includes BioMerieux SA, Cepheid,
Thermo Fisher Scientific Inc., T2 Biosystems, Inc., Abbott Laboratories, Inc., F. Hoffmann-La Roche
Ltd, Luminex Corporation, Becton, Dickinson and Company, Bruker Corporation, and Beckman
Coulter, Inc.
Recent advances in Sepsis Diagnostic Market
F.Hoffmann-La Roche in June 2016 receives the FDA clearance for its Procalcitonin (PCT) assay,
which helps clinicians to effectively assist sepsis risk and manage sepsis patients. The assay provides
the testing solution for people with severe sepsis or septic shock. Roche is the first company from U.S.
to provide fully integrated solution for sepsis risk assessment and management.
Singulex, Inc. an immunodiagnostic company engaged in developing single molecule counting (SMC)
technology for clinical diagnosis and scientific research, in December 2016 signed a license and supply
agreement with Thermo Fisher Scientific Inc. The agreement allows Singulex access to Thermo
Fisher’s BRAHMS PCT biomarker, which is used to diagnose systemic bacterial infection and
treatment of sepsis in Europe.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: [email protected]

Sepsis is life threatening complication caused due to the infection, which can result into organ failure, tissue damage, and ultimately lead to death if left untreated. If sepsis progresses to septic shock, it cause sudden drop in blood pressure and may leads to death of patient.

Download Report